Skip to main content
NCBI home page
Springer logoLink to Springer
. 2017 Dec 21;265(2):266–272. doi: 10.1007/s00415-017-8706-6

Correction to: Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials

Masahiro Nomoto 1,✉, Hirotaka Iwaki 2, Hiroyuki Kondo 3, Masaya Sakurai 3
PMCID: PMC6828037  PMID: 29270687

Correction to: Journal of Neurology https://doi.org/10.1007/s00415-017-8671-0

Unfortunately, the online published article has errors in Table 1 and Table 2. The corrected tables are given in the following page.

Table 1 Baseline characteristics in (A) full analysis set and (B) safety set in (a) combination therapy with levodopa and (b) monotherapy

(A)
(a) Combination therapy with levodopa
Elderly Non-elderly
Rotigotine Placebo Rotigotine Placebo
n n n n
Age (years), mean ± SD 86 73.6 ± 2.8 68 73.2 ± 2.7 164 61.3 ± 6.9 102 61.4 ± 7.0
Weight (kg), mean ± SD 86 52.7 ± 11.4 68 57.5 ± 10.6 164 56.1 ± 10.7 102 57.4 ± 9.4
Duration of PD (years), mean ± SD 86 7.4 ± 6.4 68 6.2 ± 3.5 164 7.0 ± 4.6 102 6.1 ± 3.9
Levodopa dose at first intervention (mg), mean ± SD 86 370.9 ± 180.9 68 342.6 ± 125.6 164 356.1 ± 145.5 102 354.2 ± 150.5
Sex (male), number (%) 86 33 (38.4) 68 40 (58.8) 164 62 (37.8) 102 46 (45.1)
HY scale, number (%)
 0 – – – – – – – –
 1 – – – – – – – –
 1.5 – – – – – – – –
 2 86 16 (18.6) 68 15 (22.1) 164 40 (24.4) 102 22 (21.6)
 2.5 86 14 (16.3) 68 12 (17.6) 164 45 (27.4) 102 25 (24.5)
 3 86 47 (54.7) 68 33 (48.5) 164 65 (39.6) 102 48 (47.1)
 4 86 9 (10.5) 68 8 (11.8) 164 14 (8.5) 102 7 (6.9)
 5 – – – – – – – –
UPDRS score, mean ± SD
 Part I 86 1.07 ± 1.34 68 1.18 ± 1.54 164 0.92 ± 1.46 102 0.71 ± 1.03
 Part II (on) 86 9.40 ± 5.59 68 9.24 ± 6.07 164 8.24 ± 5.84 102 7.20 ± 5.48
 Part II (off) 49 14.51 ± 8.36 42 16.55 ± 9.12 116 16.00 ± 8.91 75 13.97 ± 6.82
 Part II (average) 86 11.31 ± 5.78 68 11.57 ± 6.68 163 11.26 ± 6.36 102 10.12 ± 63.62
 Part III 86 27.59 ± 11.38 68 26.91 ± 10.46 164 26.10 ± 11.09 102 25.30 ± 10.29
 Part IV 86 2.87 ± 2.76 67 2.58 ± 2.35 164 3.48 ± 2.81 102 3.34 ± 2.39
(b) Monotherapy
Elderly Non-elderly
Rotigotine Placebo Rotigotine Placebo
n n n n
Age (years), mean ± SD 28 73.3 ± 2.6 31 74.2 ± 3.0 60 61.3 ± 6.9 57 61.8 ± 6.0
Weight (kg), mean ± SD 28 55.2 ± 10.9 31 54.0 ± 8.7 60 56.8 ± 9.2 57 55.4 ± 9.5
Duration of PD (years), mean ± SD 28 1.3 ± 1.3 31 1.5 ± 1.7 60 2.3 ± 1.9 57 2.0 ± 2.0
Sex (male), number (%) 28 12 (42.9) 31 14 (45.2) 60 21 (35.0) 57 23 (40.4)
HY scale, number (%)
 0 – – – – – – – –
 1 28 2 (7.1) 31 0 (0.0) 60 10 (16.7) 57 5 (8.8)
 1.5 28 3 (10.7) 31 5 (16.1) 60 5 (8.3) 57 7 (12.3)
 2 28 11 (39.3) 31 14 (45.2) 60 23 (38.3) 57 22 (38.6)
 2.5 28 5 (17.9) 31 5 (16.1) 60 6 (10.0) 57 7 (12.3)
 3 28 7 (25.0) 31 7 (22.6) 60 16 (26.7) 57 16 (28.1)
 4 – – – – – – – –
 5 – – – – – – – –
UPDRS score, mean ± SD
 Part I 28 1.00 ± 1.66 31 0.81 ± 1.01 60 0.67 ± 1.05 57 0.44 ± 0.78
 Part II 28 6.86 ± 4.72 31 8.03 ± 3.89 60 6.80 ± 3.56 57 7.12 ± 3.56
 Part III 28 20.89 ± 9.06 31 20.90 ± 9.16 60 19.82 ± 9.36 57 20.74 ± 9.77
 Part IV 28 0.25 ± 0.44 31 0.23 ± 0.43 60 0.32 ± 0.54 57 0.18 ± 0.38
(B)
(a) Combination therapy with levodopa
Elderly Non-elderly
Rotigotine Placebo Rotigotine Placebo
n n n n
Age (years), mean ± SD 87 73.6 ± 2.8 69 73.2 ± 2.6 168 61.4 ± 6.9 103 61.4 ± 7.0
Weight (kg), mean ± SD 87 52.8 ± 11.4 69 57.3 ± 10.7 168 56.0 ± 10.6 103 57.5 ± 9.6
Duration of PD (years), mean ± SD 87 7.3 ± 6.3 69 6.1 ± 3.5 168 6.9 ± 4.6 103 6.1 ± 3.9
Levodopa dose at first intervention (mg), mean ± SD 87 370.1 ± 180.0 69 342.0 ± 124.7 168 365.4 ± 196.5 103 353.6 ± 149.8
Sex (male), number (%) 87 34 (39.1) 69 40 (58.0) 168 62 (36.9) 103 47 (45.6)
HY scale, number (%)
 0 – – – – – – – –
 1 – – – – – – – –
 1.5 – – – – – – – –
 2 87 16 (18.4) 69 16 (23.2) 168 41 (24.4) 103 22 (21.4)
 2.5 87 14 (16.1) 69 12 (17.4) 168 45 (26.8) 103 25 (24.3)
 3 87 48 (55.2) 69 33 (47.8) 168 66 (39.3) 103 49 (47.6)
 4 87 9 (10.3) 69 8 (11.6) 168 16 (9.5) 103 7 (6.8)
 5 – – – – – – – –
UPDRS score, mean ± SD
 Part I 87 1.07 ± 1.33 69 1.19 ± 1.34 168 0.96 ± 1.49 103 0.70 ± 1.03
 Part II (on) 87 9.41 ± 5.56 69 9.17 ± 6.05 168 8.33 ± 5.91 103 7.18 ± 5.45
 Part II (off) 50 14.62 ± 8.31 43 16.40 ± 9.07 118 15.99 ± 8.84 76 13.95 ± 6.78
 Part II (average) 87 11.36 ± 5.76 69 11.51 ± 6.65 167 11.31 ± 6.35 103 10.11 ± 5.30
 Part III 87 27.77 ± 11.43 69 26.68 ± 10.56 168 26.47 ± 11.57 103 25.45 ± 10.34
 Part IV 87 2.90 ± 2.76 68 2.60 ± 2.34 168 3.46 ± 2.81 103 3.35 ± 2.38
(b) Monotherapy
Elderly Non-elderly
Rotigotine Placebo Rotigotine Placebo
n n n n
Age (years), mean ± SD 30 73.3 ± 2.5 31 74.2 ± 3.0 60 61.3 ± 6.9 59 61.6 ± 6.4
Weight (kg), mean ± SD 30 55.0 ± 10.5 31 54.0 ± 8.7 60 56.8 ± 9.2 59 55.4 ± 9.6
Duration of PD (years), mean ± SD 30 1.3 ± 1.3 31 1.5 ± 1.7 60 2.3 ± 1.9 59 2.1 ± 2.0
Sex (male), number (%) 30 13 (43.3) 31 14 (45.2) 60 21 (35.0) 59 25 (42.4)
HY scale, number (%)
 0 – – – – – – – –
 1 30 2 (6.7) 31 0 (0.0) 60 10 (16.7) 59 5 (8.5)
 1.5 30 3 (10.0) 31 5 (16.1) 60 5 (8.3) 59 7 (11.9)
 2 30 13 (43.3) 31 14 (45.2) 60 23 (38.3) 59 23 (39.0)
 2.5 30 5 (16.7) 31 5 (16.1) 60 6 (10.0) 59 7 (11.9)
 3 30 7 (23.3) 31 7 (22.6) 60 16 (26.7) 59 17 (28.8)
 4 – – – – – – – –
 5 – – – – – – – –
UPDRS score
 Part I 30 1.03 ± 1.61 31 0.81 ± 1.01 60 0.67 ± 1.05 59 0.42 ± 0.77
 Part II 30 6.97 ± 4.57 31 8.03 ± 3.89 60 6.80 ± 3.56 59 7.41 ± 4.64
 Part III 30 20.73 ± 8.78 31 20.90 ± 9.16 60 19.82 ± 9.36 59 21.36 ± 10.89
 Part IV 30 0.30 ± 0.53 31 0.23 ± 0.43 60 0.32 ± 0.54 59 0.17 ± 0.38
Open in a new tab

SD standard deviation, HY scale modified Hoehn and Yahr scale, UPDRS score Unified Parkinson’s Disease Rating Scale score

Table 2 Cumulative incidences of adverse events for (A) rotigotine treatment and (B) placebo: those occurring ≥ 5%, and those defined as remarkable adverse events

(A)
Adverse event (PT) Combination therapy (levodopa with rotigotine) Monotherapy (rotigotine)
Elderly (n = 87) Non-elderly (n = 168) p value† Elderly (n = 30) Non-elderly (n = 60) p value†
n Ratio (%) n Ratio (%) n Ratio (%) n Ratio (%)
Total 76 87.4 155 92.3 0.2034 24 80.0 54 90.0 0.1883
Application site reactions 37 42.5 98 58.3 0.0165 10 33.3 32 53.3 0.0730
Nasopharyngitis 17 19.5 29 17.3 0.6537 4 13.3 7 11.7 0.8200
Nauseaa 15 17.2 27 16.1 0.8113 2 6.7 19 31.7 0.0082
Dyskinesia 9 10.3 30 17.9 0.1141 0 0.0 1 1.7 0.4770
Somnolencea 6 6.9 17 10.1 0.3944 6 20.0 7 11.7 0.2891
Visual hallucinationa 8 9.2 13 7.7 0.6882 1 3.3 2 3.3 1.0000
Vomitinga 6 6.9 14 8.3 0.6858 2 6.7 12 20.0 0.0999
Contusion 7 8.0 6 3.6 0.1235 1 3.3 0 0.0 0.1550
Loss of appetite 5 5.7 7 4.2 0.5721 2 6.7 3 5.0 0.7449
Blood creatinine phosphokinase increase 3 3.4 9 5.4 0.4950 1 3.3 3 5.0 0.7176
Application site pruritus 5 5.7 6 3.6 0.4175 0 0.0 0 0.0 –
Dizziness 7 8.0 4 2.4 0.0348 0 0.0 0 0.0 –
Fall 5 5.7 5 3.0 0.2798 0 0.0 0 0.0 –
Orthostatic hypotensiona 1 1.1 6 3.6 0.2618 0 0.0 0 0.0 –
Hallucinationa 4 4.6 2 1.2 0.0888 4 13.3 0 0.0 0.0038
Auditory hallucinationa 0 0.0 3 1.8 0.2099 0 0.0 0 0.0 –
Delusiona 1 1.1 2 1.2 0.9770 0 0.0 0 0.0 –
Sudden onset of sleepa 1 1.1 0 0.0 0.1638 1 3.3 0 0.0 0.1550
Constipation 3 3.4 8 4.8 0.6245 3 10.0 9 15.0 0.5107
Insomnia 0 0.0 6 3.6 0.0745 2 6.7 4 6.7 1.0000
Back pain 0 0.0 6 3.6 0.0745 2 6.7 1 1.7 0.2129
Diarrhea 2 2.3 2 1.2 0.4995 0 0.0 3 5.0 0.2129
Weight loss 1 1.1 2 1.2 0.9770 2 6.7 0 0.0 0.0431
Peripheral edema 1 1.1 1 0.6 0.6343 2 6.7 0 0.0 0.0431
Hypokalemia 0 0.0 0 0.0 – 2 6.7 0 0.0 0.0431
(B)
Adverse event (PT) Combination therapy (levodopa with placebo) Monotherapy (placebo)
Elderly (n = 69) Non-elderly (n = 103) Elderly (n = 31) Non-elderly (n = 59)
n Ratio (%) n Ratio (%) n Ratio (%) n Ratio (%)
Total 53 76.8 83 80.6 19 61.3 46 78.0
Application site reactions 9 13.0 17 16.5 6 19.4 14 23.7
Nasopharyngitis 11 15.9 15 14.6 4 12.9 11 18.6
Nauseaa 4 5.8 8 7.8 0 0.0 5 8.5
Dyskinesia 3 4.3 5 4.9 0 0.0 0 0.0
Somnolencea 1 1.4 2 1.9 1 3.2 3 5.1
Visual hallucinationa 2 2.9 3 2.9 0 0.0 0 0.0
Vomitinga 1 1.4 2 1.9 1 3.2 0 0.0
Contusion 2 2.9 7 6.8 3 9.7 4 6.8
Loss of appetite 1 1.4 2 1.9 0 0.0 0 0.0
Blood creatinine phosphokinase increase 1 1.4 3 2.9 1 3.2 1 1.7
Application site pruritus 2 2.9 2 1.9 0 0.0 0 0.0
Dizziness 1 1.4 2 1.9 2 6.5 2 3.4
Fall 2 2.9 6 5.8 1 3.2 1 1.7
Orthostatic hypotensiona 4 5.8 2 1.9 0 0.0 1 1.7
Hallucinationa 2 2.9 1 1.0 0 0.0 0 0.0
Auditory hallucinationa 0 0.0 1 1.0 0 0.0 0 0.0
Delusiona 0 0.0 0 0.0 0 0.0 0 0.0
Sudden onset of sleepa 0 0.0 0 0.0 0 0.0 0 0.0
Constipation 2 2.9 1 1.0 1 3.2 4 6.8
Insomnia 2 2.9 2 1.9 0 0.0 2 3.4
Back pain 2 2.9 4 3.9 0 0.0 1 1.7
Diarrhea 1 1.4 2 1.9 2 6.5 1 1.7
Weight loss 0 0.0 0 0.0 0 0.0 0 0.0
Peripheral edema 1 1.4 3 2.9 0 0.0 0 0.0
Hypokalemia 0 0.0 0 0.0 0 0.0 0 0.0
Open in a new tab

aSymptom defined as a remarkable adverse event

†For comparison between elderly and non-elderly groups

Footnotes

The original article can be found online at https://doi.org/10.1007/s00415-017-8671-0.

Articles from Journal of Neurology are provided here courtesy of Springer

RESOURCES